Lichen planus (LP) is a chronic inflammatory dis-ease that typically affects the skin and mucous membranes. Inflammation has been shown to affect lipid and carbohydrate metabolism, insulin signaling, and adipogenesis (1). Adipose tissue is an active endocrine organ that secrete numerous factors such as adiponectin, which influence carbohydrate and lipid metabo-lism (2). Low plasma adiponectin levels have been reported in a variety of conditions, includ-ing obesity, type 2 diabetes, and LP (2, 3). How-ever, whether these differences in adiponectin levels in LP are due to the high prevalence of comorbidities such as diabetes and obesity or the sole effects of disease on adiponectin is not ob-vious. In this study, we examined the lipid profile and serum adiponectin levels in patients with LP and healthy controls. Thirty-nine patients diagnosed with LP and 19 controls were included. All participants signed an informed consent form before the study. This report was approved by the local ethics commit-tee. Blood samples were taken after a 12 hour fast. An enzyme-linked immunosorbent assay (ELISA) method was applied to determine serum adiponectin levels. Dyslipidemia was defined as total cholesterol (TC) > 200 mg / dl, low-density lipoprotein cho-lesterol (LDL) > 130 mg / dl, triglyceride (TG) > 150 mg / dl and high-density lipoprotein choles-terol (HDL) < 40 mg / dl in men or HDL < 50 mg / dl in women (4). Central obesity was de-fined as a waist circumference of at least 88 cm in women and 102 cm in men (5). The independent t-test, chi-square test, correla-tion analysis, and regression were used to exam-ine differences between the two groups. Statisti-cal analysis was performed with SPSS version 19 (IBM Corp., Armonk, NY, USA). Of 39 patients, 20 (51. 3%) had oral involvement and 19 (48. 7%) had cutaneous involvement. The patient and control groups showed no significant differences in terms of age and gender. The patients had a significantly larger mean waist circumference than the controls (P= 0. 013). Ac-cording to the frequency of participants with cen-tral obesity or dyslipidemia, no significant differ-ences were found between patients and controls. Serum TG levels were significantly higher in pa-tients than in controls (P = 0. 030). In addition, the patients had significantly lower serum adi-ponectin levels than the controls (P=0. 004). There was a positive correlation between serum adiponectin and HDL levels in patients (correla-tion (r) = 0. 346,P= 0. 031). A backward linear regression model showed that LP was associated with adiponectin levels even after adjusting for dyslipidemia, FBS, and obesity (B = 0. 307,β,= 0. 373,t = 3. 006,P= 0. 004). However, concerning the above parameters, no significant differences were observed between patients with oral and cutaneous involvement. Various interleukins (ILs) are elevated in LP pa-tients, which may play an essential role in the de-velopment of dyslipidemia (6). Panchal et al ob-served significantly higher TC, TG, and LDL lev-els and lower HDL levels in LP patients com-pared to controls (7). Conversely, Ö, zkur et al found no significant differences in serum levels of TC, LDL, and TG between patients with LP and controls (8). Our study showed significantly higher TG levels in patients with LP than in controls. However, no significant differences were observed between the two groups concerning other parameters of the lipid profile. The different ranges of LP duration in this study may have influenced lipid profiles of patients. Our study also showed that patients with LP had significantly lower serum adiponectin levels than controls. Similarly, Ismail et al found significantly lower serum adiponectin levels in LP patients (3). The prevalence of comorbidities such as diabetes and dyslipidemia is higher in patients with LP (1). Patients with obesity, diabetes, and dyslipidemia often have low levels of adiponectin (9). Howev-er, we found that LP was associated with lower plasma adiponectin levels regardless of dyslipidemia, diabetes, and obesity. We suggest that lower adiponectin levels in LP patients are not entirely due to the high rate of comorbidities in LP, but rather to a unique effect of LP on adi-pose tissue function and adiponectin signaling. These results may be due to the complex interac-tions between elevated levels of various cytokines and adipose tissue in LP. In conclusion, early lipid profile screening in LP patients may not be of great value and inflamma-tion present in LP may be associated with adi-pose tissue dysfunction.